Multiple Sclerosis – TG Therapeutics TG1101-RMS406

Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.

The purpose of this study is to evaluate safety, effectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting.

Inclusion Criteria:

  • Confirmed Multiple Sclerosis (MS) diagnosis.
  • Participants who have not received any BRIUMVI® (ublituximab-xiiy) infusion prior to study start. Participants who have been prescribed BRIUMVI® (ublituximab-xiiy) but have not yet received their first infusion on Day 1 of 150 milligrams (mg) can be included.

Complete the form to get connected with new research studies and our team will reach out soon to help determine your eligibility.

View Study on ClinicalTrials.gov

Trial Interest Form

Locations

MHP Rochester - Oakland Medical Group

633 E South Blvd
Suite 1100
Rochester Hills, Michigan